Stay updated with breaking news from Rachel Eides. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZUG, Switzerland and BOSTON, March 29, 2023 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that... | March 29, 2023
ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases
Oral presentation of encore clinical data from Phase 3 clinical trials of exa-cel - Oral and poster presentations on quality-of-life impacts of sickle cell disease or transfusion-dependent beta-thalassemia
01.11.2022 - -Exagamglogene autotemcel (exa-cel), formerly known as CTX001 submission to the U.S. Food and Drug Administration (FDA) for rolling review expected to begin in November, with completion of the U.S. submission package expected in Q1 2023; EMA and ...
ZUG, Switzerland and BOSTON, Sept. 28, 2022 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that... | September 28, 2022